Literature DB >> 25439696

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

S Vincent Rajkumar1, Meletios A Dimopoulos2, Antonio Palumbo3, Joan Blade4, Giampaolo Merlini5, María-Victoria Mateos6, Shaji Kumar7, Jens Hillengass8, Efstathios Kastritis2, Paul Richardson9, Ola Landgren10, Bruno Paiva11, Angela Dispenzieri7, Brendan Weiss12, Xavier LeLeu13, Sonja Zweegman14, Sagar Lonial15, Laura Rosinol4, Elena Zamagni16, Sundar Jagannath17, Orhan Sezer18, Sigurdur Y Kristinsson19, Jo Caers20, Saad Z Usmani21, Juan José Lahuerta22, Hans Erik Johnsen23, Meral Beksac24, Michele Cavo16, Hartmut Goldschmidt8, Evangelos Terpos2, Robert A Kyle7, Kenneth C Anderson9, Brian G M Durie25, Jesus F San Miguel11.   

Abstract

This International Myeloma Working Group consensus updates the disease definition of multiple myeloma to include validated biomarkers in addition to existing requirements of attributable CRAB features (hypercalcaemia, renal failure, anaemia, and bone lesions). These changes are based on the identification of biomarkers associated with near inevitable development of CRAB features in patients who would otherwise be regarded as having smouldering multiple myeloma. A delay in application of the label of multiple myeloma and postponement of therapy could be detrimental to these patients. In addition to this change, we clarify and update the underlying laboratory and radiographic variables that fulfil the criteria for the presence of myeloma-defining CRAB features, and the histological and monoclonal protein requirements for the disease diagnosis. Finally, we provide specific metrics that new biomarkers should meet for inclusion in the disease definition. The International Myeloma Working Group recommends the implementation of these criteria in routine practice and in future clinical trials, and recommends that future studies analyse any differences in outcome that might occur as a result of the new disease definition.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25439696     DOI: 10.1016/S1470-2045(14)70442-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  970 in total

1.  Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.

Authors:  Jagoda K Jasielec; Tadeusz Kubicki; Noopur Raje; Ravi Vij; Donna Reece; Jesus Berdeja; Benjamin A Derman; Cara A Rosenbaum; Paul Richardson; Sandeep Gurbuxani; Sarah Major; Brittany Wolfe; Andrew T Stefka; Leonor Stephens; Kathryn M Tinari; Tyler Hycner; Alexandra E Rojek; Dominik Dytfeld; Kent A Griffith; Todd M Zimmerman; Andrzej J Jakubowiak
Journal:  Blood       Date:  2020-11-26       Impact factor: 22.113

Review 2.  Imaging in myeloma with focus on advanced imaging techniques.

Authors:  Tara Barwick; Laure Bretsztajn; Kathryn Wallitt; Dimitri Amiras; Andrea Rockall; Christina Messiou
Journal:  Br J Radiol       Date:  2019-01-03       Impact factor: 3.039

Review 3.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

Review 4.  Functional and molecular MRI of the bone marrow in multiple myeloma.

Authors:  Vassilis Koutoulidis; Nickolas Papanikolaou; Lia A Moulopoulos
Journal:  Br J Radiol       Date:  2018-02-13       Impact factor: 3.039

5.  Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis.

Authors:  Ahmad Masri; Syed Bukhari; Shahzad Ahmad; Ricardo Nieves; Yvonne S Eisele; William Follansbee; Amy Brownell; Timothy C Wong; Erik Schelbert; Prem Soman
Journal:  Circ Cardiovasc Imaging       Date:  2020-02-17       Impact factor: 7.792

Review 6.  Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney-What We Know and What the Future May Hold.

Authors:  Sandhya Manohar; Samih H Nasr; Nelson Leung
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 7.  Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?

Authors:  Hira S Mian; Tanya M Wildes
Journal:  Drugs Aging       Date:  2018-04       Impact factor: 3.923

Review 8.  Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.

Authors:  P Fabbrini; K Finkel; M Gallieni; G Capasso; M Cavo; A Santoro; S Pasquali
Journal:  J Nephrol       Date:  2016-10-18       Impact factor: 3.902

9.  Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.

Authors:  James E McDonald; Marcus M Kessler; Michael W Gardner; Amy F Buros; James A Ntambi; Sarah Waheed; Frits van Rhee; Maurizio Zangari; Christoph J Heuck; Nathan Petty; Carolina Schinke; Sharmilan Thanendrarajan; Alan Mitchell; Antje Hoering; Bart Barlogie; Gareth J Morgan; Faith E Davies
Journal:  Clin Cancer Res       Date:  2016-10-03       Impact factor: 12.531

10.  Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation.

Authors:  Christos Sachpekidis; J Hillengass; H Goldschmidt; B Wagner; U Haberkorn; K Kopka; A Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-29       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.